Survival and freedom from reoperation after the Ross procedure in a Russian adult population: A single-center experienceCentral MessagePerspective
Bashir Tsaroev, MD,
Igor Chernov, MD, PhD,
Soslan Enginoev, MD, PhD,
Muslim Mustaev, MD, PhD
Affiliations
Bashir Tsaroev, MD
Federal State Budgetary Institution “Federal Center for Cardiovascular Surgery” of the Ministry of Health of the Russian Federation, Astrakhan, Astrakhan Region, Russia; Department of Vascular Surgery, Alexandro-Mariinsky Regional Clinical Hospital, Astrakhan, Astrakhan Region, Russia; Address for reprints: Bashir Tsaroev, MD, Department of Vascular Surgery, Alexandro-Mariinsky Regional Clinical Hospital, 2 Tatisheva, Astrakhan, Astrakhan region, Russia, 414041.
Igor Chernov, MD, PhD
Federal State Budgetary Institution “Federal Center for Cardiovascular Surgery” of the Ministry of Health of the Russian Federation, Astrakhan, Astrakhan Region, Russia
Soslan Enginoev, MD, PhD
Federal State Budgetary Institution “Federal Center for Cardiovascular Surgery” of the Ministry of Health of the Russian Federation, Astrakhan, Astrakhan Region, Russia; Department of Cardiovascular Surgery, Astrakhan State Medical University, Astrakhan, Astrakhan Region, Russia
Muslim Mustaev, MD, PhD
Department of Adult Cardiac Surgery, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Objectives: To evaluate our 12-year experience with the Ross procedure in adults. Methods: A retrospective analysis of 215 cases of the Ross procedure was performed. The mean age of the patients was 36 ± 11.1 years, and the male to female ratio was 75% to 25%, respectively. The pulmonary autograft was placed into the aortic position using the full-root replacement technique and its modified versions. The right ventricular outflow tract was reconstructed using a pulmonary homograft in all cases. Results: The 30-day mortality after the operation was 0.9% (2 patients). The median duration of follow-up was 6.1 years (interquartile range, 6.5 years) and was complete in 86% of cases. The survival at 12 years was 94.7% and was comparable with the survival rate of the general population matched for age and sex. At the end of the follow-up, freedom from reoperation due to pulmonary autograft and homograft dysfunction was 89.1% and 99%, respectively. Conclusions: In our series, the Ross procedure resulted in low early mortality and excellent survival in adults. The long-term survival was not statistically different from the survival of the general population. The pulmonary homograft offered an excellent durability and freedom from reoperation.
